profit from every $100 of sales.
$0$100
Acrivon Therapeutics
$1.57+0.00% today
-24.2% in 1 year
1-year low $1.291-year high $3.01
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Acrivon Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$77.9 million of profit last year.
SalesProfit
Acrivon Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Acrivon Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Acrivon Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -33 | -67 | -89 | -84 | |
| -32 | -67 | -88 | -83 | |
| -31 | -60 | -81 | -78 | |
| -7.56 | -2.74 | -2.38 | -2.02 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 181 | 138 | 197 | 130 |
| Cash | 30 | 36 | 40 | 41 |
| Total debt | 5 | 5 | 4 | 3 |
| Total liabilities | 11 | 17 | 20 | 17 |
| 170 | 121 | 177 | 113 | |
| 4 | 22 | 34 | 39 | |
| -14.7% | -42.1% | -39.1% | -57.7% | |
| -18.3% | -49.8% | -45.6% | -69.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -30 | -43 | -66 | -64 | |
| 2 | 1 | 3 | 2 | |
| -32 | -44 | -68 | -65 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 2 | 12 | 14 | 15 |
Valuation
- –
- –
- –
- 0.7×
- –
- –
- –
- -97.1%
- -115.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -84.1%
- -17.7%
- -64.4%
- -71.7%
- -85.1%
- –
Growth
- –
- –
- +4.5%
- –
- +31.4%
Financial health
- 0.4×
- 0.03
- 2.2%
- –
- 8.98
- 8.98
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 958
Bottom 21%of 888
Bottom 1%of 987
What analysts expect
- Average price target
- $21.83
- Range
- $17.00 – $30.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.49 | -0.49 | +0.0% |
| Mar 19, 2026 | -0.49 | -0.49 | +0.0% |
| Nov 13, 2025 | -0.47 | -0.57 | +17.5% |
| Aug 13, 2025 | -0.55 | -0.57 | +3.5% |
| May 14, 2025 | -0.51 | -0.57 | +10.5% |
| Mar 27, 2025 | -0.60 | -0.69 | +13.0% |
| Nov 13, 2024 | -0.59 | -0.56 | −5.4% |
| Aug 13, 2024 | -0.52 | -0.59 | +11.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
75Pass
Philip Fisher
32No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
25No pass
Questions about Acrivon Therapeutics
Is Acrivon Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Acrivon Therapeutics AI analysis
What does Acrivon Therapeutics do?
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. It is in Biotechnology.
Does Acrivon Therapeutics pay a dividend?
No. Acrivon Therapeutics does not pay a dividend at the moment.
Is Acrivon Therapeutics stock halal?
No. Acrivon Therapeutics does not pass our halal screen: its cash and confirmed interest-bearing investments are 62% of its market value, at or above the 33% limit. How we check
How has Acrivon Therapeutics stock done over the past year?
Down 24.2% over the past twelve months, to $1.57. It traded between $1.29 and $3.01 and is 47.8% below its high.
Who are Acrivon Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Acrivon Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.